In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|January 22, 2026
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging markets, why site-centric practices are becoming critical to faster study activation, and how a new Pfizer–Novavax agreement reflects shifting vaccine development strategies.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- A new Applied Clinical Trials contributed
article examines how global clinical development has become more technology-enabled, regulated, and geographically diversified. Emerging markets—particularly in Asia-Pacific and China—are driving a growing share of trial starts, while decentralized and hybrid trial models are expanding access and participation. The article highlights how CRO partnerships, digital platforms, and evolving regulatory guidance are reshaping global trial execution around scale, speed, and patient-centricity. - In the final installment of his Applied Clinical Trials video
interview , Brian Mallon of ICON says accelerating study startup requires sponsors and CROs to better center the human experience of site staff. He emphasizes the importance of genuine site partnerships, clearer timelines, and meeting sites within their existing systems and workflows. Mallon notes that valuing site expertise and engagement is essential to maintaining momentum and improving activation performance. - Novavax has entered a non-exclusive licensing
agreement with Pfizer worth up to $530 million, granting Pfizer access to Novavax’s Matrix-M adjuvant technology for vaccine development. The deal includes $30 million upfront and potential milestone payments and royalties, with Pfizer responsible for development and commercialization. Executives say the agreement reflects Novavax’s shift toward partnership-driven growth and strengthens Pfizer’s access to diversified vaccine platforms.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
3
Where AI Leads in Trial Design—and Where Humans Still Need To
4
ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment
5